- $19.98m
- $20.33m
- $48.67m
- 40
- 36
- 32
- 28
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 9.53 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.41 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -66.01% | ||
| Return on Equity | -125.84% | ||
| Operating Margin | -17.06% | ||
Financial Summary
| Year End 28th Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 36.35 | 53.9 | 56.97 | 51.87 | 48.67 | 52.3 | n/a | 2.3% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
IRIDEX Corporation is an ophthalmic medical technology company. It develops and commercializes products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its MicroPulse Technology and Endpoint Management Technology are used for the treatment of glaucoma and retina disorders. Its laser consoles product consists of Glaucoma, Medical Retina and Surgical Retina. Its glaucoma console line is the Cyclo G6 laser system with MicroPulse technology. Its surgical-retina product line includes its OcuLight TX and OcuLight SLx laser photocoagulation systems. Its medical-retina product line includes its portable IQ 532 and IQ 577 laser systems. Its laser probes products include Glaucoma and Surgical Retina. Probes used in its glaucoma product line include its patented single-use delivery devices-MicroPulse P3, G-Probe, and G-Probe Illuminate. Probes used in its surgical retina product line include its family of single-use EndoProbe handpieces.
Directors
- Scott Shuda NEC (55)
- David Bruce PRE (61)
- Fuad Ahmad CFO (51)
- Patrick Mercer COO (49)
- Nandini Devi IND (47)
- Robert Grove IND (72)
- Kenneth Ludlum IND (67)
- Last Annual
- December 28th, 2024
- Last Interim
- December 28th, 2024
- Incorporated
- November 21st, 1995
- Public Since
- February 16th, 1996
- No. of Shareholders
- 33
- No. of Employees
- 93
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 16,789,027
- Address
- 1212 Terra Bella Ave, MOUNTAIN VIEW, 94043-1824
- Web
- https://www.iridex.com/
- Phone
- +1 6509404700
- Auditors
- BPM LLP
Upcoming Events for IRIX
Q1 2025 IRIDEX Corp Earnings Call
IRIDEX Corp Annual Shareholders Meeting
IRIDEX Corp Annual Shareholders Meeting
Q2 2025 IRIDEX Corp Earnings Release
Q3 2025 IRIDEX Corp Earnings Release
Similar to IRIX
Accelerate Diagnostics
NASDAQ Capital Market
Adagio Medical Holdings
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
FAQ
What is the IRIDEX share price?
As of Today at 21:23 UTC, shares in IRIDEX are trading at $1.19. This share price information is delayed by 15 minutes.
How has the IRIDEX share price performed this year?
Shares in IRIDEX last closed at $1.19 and the price had moved by -58.24% over the past 365 days. In terms of relative price strength the IRIDEX share price has underperformed the S&P500 Index by -62.34% over the past year.
What are the analyst and broker recommendations for IRIDEX?
The overall consensus recommendation for IRIDEX is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the IRIDEX dividend yield?
IRIDEX does not currently pay a dividend.
Does IRIDEX pay a dividend?
IRIDEX does not currently pay a dividend.
When does IRIDEX next pay dividends?
IRIDEX does not currently pay a dividend.
How do I buy IRIDEX shares?
To buy shares in IRIDEX you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of IRIDEX?
As of the previous close price of $1.19, shares in IRIDEX had a market capitalisation of $19.98m.
Where are IRIDEX shares listed?
Here are the trading details for IRIDEX:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: IRIX
What kind of share is IRIDEX?
Based on an overall assessment of its quality, value and momentum IRIDEX is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a IRIDEX share price forecast for 2025?
The analyst consensus target price for shares in IRIDEX is $2.00. That is 68.07% above the last closing price of $1.19.
Analysts covering IRIDEX currently have a consensus Earnings Per Share (EPS) forecast of -$0.27 for the next financial year.
Find out moreWhat is the trend in the IRIDEX share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like IRIDEX. Over the past six months, its share price has underperformed the S&P500 Index by -20.04%.
As of the last closing price of $1.19, shares in IRIDEX were trading -25.02% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the IRIDEX PE Ratio?
The IRIDEX PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.19.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of IRIDEX?
IRIDEX's management team is headed by:
- Scott Shuda - NEC
- David Bruce - PRE
- Fuad Ahmad - CFO
- Patrick Mercer - COO
- Nandini Devi - IND
- Robert Grove - IND
- Kenneth Ludlum - IND